Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 11/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 7/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.39 |
| ▸ | IARS1 | P41252 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2777940 | 1.00 | DPP4 (0.43) | DPP4DPP8DPP9ALOX15DPP7 | |
| Hydrochloric Acid SCHEMBL4277313 | 1.00 | DPP4 (0.43) | DPP4DPP8DPP9ALOX15DPP7 | |
| Hydrochloric Acid SCHEMBL29087500 | 1.00 | DPP4 (0.43) | DPP4DPP8DPP9ALOX15DPP7 | |
| Hydrochloric Acid SCHEMBL28778377 | 0.98 | DPP4 (0.42) | DPP4DPP8DPP9ALOX15DPP7 | |
| SCHEMBL199058 | 0.98 | DPP4 (0.44) | DPP4DPP8DPP9ALOX15DPP7 | |
| SCHEMBL20902879 | 0.98 | DPP4 (0.44) | DPP4DPP8DPP9ALOX15DPP7 | |
| SCHEMBL29087496 | 0.98 | DPP4 (0.44) | DPP4DPP8DPP9ALOX15DPP7 | |
| SCHEMBL13482942 | 0.98 | DPP4 (0.44) | DPP4DPP8DPP9ALOX15DPP7 | |
| SCHEMBL1685517 | 0.98 | DPP4 (0.44) | DPP4DPP8DPP9ALOX15DPP7 | |
| SCHEMBL30552158 | 0.98 | DPP4 (0.44) | DPP4DPP8DPP9ALOX15DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122056386-A | Moisture absorption resistant slow release microcapsule powder and preparation method and application thereof | 大连医诺生物股份有限公司 | 2026-05-19 | — | — | CN | claimed |
| CN-122030612-A | Shear-resistant slow-release microcapsule powder and preparation method and application thereof | 大连医诺生物股份有限公司 | 2026-05-15 | — | — | CN | claimed |
| CN-115991938-B | Polyphosphazene polymer hydrogel and preparation method and application thereof | 深圳市罗湖区中医院 | 2024-03-15 | — | — | CN | claimed |
| CN-115991938-A | Polyphosphazene polymer hydrogel and preparation method and application thereof | 深圳市罗湖区中医院 | 2023-04-21 | — | — | CN | claimed |
| CN-114835616-A | Caffeoyl amino acid ethyl ester and preparation method and application thereof | 珀莱雅化妆品股份有限公司 | 2022-08-02 | — | — | CN | claimed |
| CN-114456108-A | N-amino acid ethyl ester nicotinamide and preparation method and application thereof | 珀莱雅化妆品股份有限公司 | 2022-05-10 | — | — | CN | claimed |
| EP-3817812-A1 | CRYSTALLINE SALT OF 5-METHYL-(6S)-TETRAHYDROFOLIC ACID AND L-ISOLEUCINE ETHYL ESTER | Merck Patent GmbH (DE) | 2021-05-12 | — | — | EP | claimed |
| CN-112351818-A | Crystalline salts of 5-methyl- (6S) -tetrahydrofolic acid and ethyl L-isoleucine | 默克专利股份有限公司 | 2021-02-09 | — | — | CN | claimed |
| WO-2020007836-A1 | CRYSTALLINE SALT OF 5-METHYL-(6S)-TETRAHYDROFOLIC ACID AND L-ISOLEUCINE ETHYL ESTER | MERCK PATENT GMBH (DE) | 2020-01-09 | — | — | WO | claimed |
| CN-122056386-A | Moisture absorption resistant slow release microcapsule powder and preparation method and application thereof | 大连医诺生物股份有限公司 | 2026-05-19 | — | — | CN | disclosed |
| CN-122030612-A | Shear-resistant slow-release microcapsule powder and preparation method and application thereof | 大连医诺生物股份有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20250367169-A1 | FORMULATIONS FOR PERSONALIZED METHODS OF TREATMENT | FAETH THERAPEUTICS INC (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4537813-A1 | COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, CONTAINING POLY(ORGANOPHOSPHAZENE) POLYMER | Korea Institute of Science and Technology (KR) | 2025-04-16 | — | — | EP | disclosed |
| US-12220402-B2 | Formulations for personalized methods of treatment | FAETH THERAPEUTICS, INC. (US) | 2025-02-11 | — | — | US | disclosed |
| US-20070042988-A1 | Antiviral phosphoramidates | ROCHE PALO ALTO LLC | 2007-02-22 | — | — | US | disclosed |
| CN-1033701-C | Process for preparing 9- (2-hydroxyethoxymethyl) guanine derivatives | WELLCOME FOUND (GB) | 1997-01-01 | — | — | CN | disclosed |
| WO-1992016552-A1 | 1-IMIDAZOLGEMETHYL BENZOFURAN DERIVATIVES AS INHIBITORS OF ANGIOTENSIN II ACTIVITY | GLAXO GROUP LIMITED (GB) | 1992-10-01 | — | — | WO | disclosed |
| EP-0505954-A1 | N-Imidazolylmethyl benzofuran derivatives as inhibitors of angiotensin II activity | GLAXO GROUP LIMITED (GB) | 1992-09-30 | — | — | EP | disclosed |
| CN-1032538-A | THERAPEUTIC ACYCLIC NUCLEOSIDES | WELLCOME FOUND (GB) | 1989-04-26 | — | — | CN | disclosed |
| US-4616002-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1986-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070042988-A1 | Antiviral phosphoramidates | RPP30, RNASE1, ADORA2B | DPP4 984/4885DPP8 1728/4885DPP9 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.